Dose Accumulation with CBCT Conversion in Head and Neck and Prostate
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Methods

Background

Rigid Registration

❖In standard radiotherapy, only one planning CT ❖Planning CTs, weekly CTs, and daily CBCTs
were imported into a commercial treatment
is used but the size and position of the tumor
planning system (TPS), RayStation (RaySearch
and organs at risk (OARs) changes during
Laboratories, Stockholm, Sweden)
treatment
❖Specifically, in head and neck cancers patients ❖First, rigid registrations were applied. Then,
lose weight and the parotid glands shrink during ANACONDA hybrid intensity DIR’s were
created. CBCT conversion was performed using
treatment and in the prostate the size of the
bladder varies fraction-to-fraction (see Figure 1) the commercial algorithm that uses DIR
❖Dose was evaluated in the TPS on all images.
❖Daily cone beam (CT) is already used in the
Dose on weekly CTs, daily CBCTs, and
clinic for patient positioning
corrected CBCTs was deformed to the planning
❖CBCT is easy to acquire via on-board imagers
CT image. Finally, dose was accumulated on
but provides limited field of view and is of
the planning CT and dose differences were
poorer quality than CT
qualitatively evaluated
❖Correcting CBCT via deformable image
registration (DIR) enables “dose of the day”
calculations

DIR

Figure 1. Rigid and deformable image registration
performed between planning CT and last day CBCT
corrected with primary CT. Image differences are shown
in blue and orange. Overlapping areas are in shades of
gray.

Results

Figure 2. Right
(magenta)
and
left (blue) parotid
glands as seen
on CBCT on the
first day (day 1)
(solid line) and
last day (day 33)
(dashed line) of
treatment.
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Figure 4. Representative CT, CBCT, and corrected CBCT sagittal images of prostate (top row)
and head and neck (bottom row) patients. GTV: gross target volume, CTV: clinical target
volume, PTV: planning target volume.

Conclusions

Figure 3. Representative axial dose difference
images of a head and neck patient where a
dose difference between planning and
accumulated with CBCT dose was observed
inside an organ at risk.

(c)

(b)
(d)

❖CBCTs were successfully converted
❖Transition areas between the CT and CBCT were smooth
❖Dose was calculated on CBCT’s and corrected CBCT’s
❖Dose differences were observed between planning CT and
accumulated CBCT ; clinical impact is being determined
❖No dose differences were observed between CBCT’s
corrected with primary and with weekly inside organs at risk
.

Figure 5. Accumulated dose on CBCTs corrected
with primary (a) and weekly CT (b). The dose
difference (c) and Dose Volume Histogram (d) are
also shown for a representative head and neck
patient. GTV: gross target volume, OARs: Organs
at Risk.
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